Dasatinib suppresses in vitro natural killer cell cytotoxicity.
Blake
Stephen J
SJ
Bruce Lyons
A
A
Fraser
Cara K
CK
Hayball
John D
JD
Hughes
Timothy P
TP
D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D000069439:Dasatinib; D006801:Humans; D019169:Jurkat Cells; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000166:cytology* / Q000187:drug effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011948:Receptors, Antigen, T-Cell; D013844:Thiazoles; D019061:src-Family Kinases; D000069439:Dasatinib